En bref :
Multiple clinical failures in the neurodegenerative field have sparked realisation that there is a critical need for discussion and debate between neurodegenerative drug developers to drive clinical success.
NDD Europe will overcome the translational challenges facing neurodegenerative drug developers by exploring the future biomarkers of neurodegeneration, improving preclinical modelling to increase clinical predictability and encouraging precompetitive strategies and collaboration amongst drug developers.
With 70+ thought-leaders converging at NDD Europe, this will be an unrivalled opportunity for you to gain the latest scientific insights, have your peers review your research and grow your collaborator network. Key talks form industry experts will address:
- Seeking blood-based biomarkers to advance patient stratification and diagnosis
- Assessing CSF-based and imaging biomarker techniques to improve biomarker translatability
- Exploring novel preclinical models for neurodegeneration to allow disease recapitulation
- Evaluating different approaches for targeting neurodegeneration and efficiently crossing the blood-brain barrier for drug delivery and target engagement
NDD Europe will provide a platform for creative thinking, encouraging debate and communication to enable the neurodegeneration field to shape their future research with reduced risk and greater efficiency.
on Tuesday May 21, 2019 at 10:00 am (ends Thursday May 23, 2019 at 5:00 pm)
